413 related articles for article (PubMed ID: 21677471)
1. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
Cervera P; Fléjou JF
Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
[TBL] [Abstract][Full Text] [Related]
2. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD
Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
[TBL] [Abstract][Full Text] [Related]
3. Genetics of hepatobiliary carcinogenesis.
Nault JC; Zucman-Rossi J
Semin Liver Dis; 2011 May; 31(2):173-87. PubMed ID: 21538283
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies in gastrointestinal cancers.
Bronte G; Cicero G; Cusenza S; Galvano A; Musso E; Rizzo S; Sortino G; Roselli M; Bazan V; Fiorentino E; Russo A
Expert Opin Biol Ther; 2013 Jun; 13(6):889-900. PubMed ID: 23441760
[TBL] [Abstract][Full Text] [Related]
5. Predictors of response to targeted therapies for gastrointestinal stromal tumors.
Marrari A; Wagner AJ; Hornick JL
Arch Pathol Lab Med; 2012 May; 136(5):483-9. PubMed ID: 22229850
[TBL] [Abstract][Full Text] [Related]
6. Involvement of signaling molecules in the prediction of response to imatinib treatment in metastatic GIST patients.
Valadão M; Braggio D; Santos AF; Pimenta-Inada HK; Linhares E; Gonçalves R; Romano S; Vilhena B; Small I; Cubero D; Cruz F; Oliveira AT; Martinho O; Reis RM; Guimarães DP; Ferreira CG
J Surg Res; 2012 Nov; 178(1):288-93. PubMed ID: 22516345
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapies and predictive markers in epithelial malignancies of the gastrointestinal tract.
McIntire M; Redston M
Arch Pathol Lab Med; 2012 May; 136(5):496-503. PubMed ID: 22229849
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of c-erbB-2 gene expression in pancreatic cancer patients.
Novotný J; Petruzelka L; Vedralová J; Kleibl Z; Matous B; Juda L
Neoplasma; 2001; 48(3):188-91. PubMed ID: 11583287
[TBL] [Abstract][Full Text] [Related]
9. Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.
López RL; del Muro XG
Anticancer Drugs; 2012 Jun; 23 Suppl():S3-6. PubMed ID: 22739667
[TBL] [Abstract][Full Text] [Related]
10. Established and Potential Predictive Biomarkers in Gastrointestinal Cancer--c-Kit, Her2, Ras and Beyond.
Koch C; Trojan J
Digestion; 2015; 91(4):294-302. PubMed ID: 25924988
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
Demetri GD; von Mehren M; Blanke CD; Van den Abbeele AD; Eisenberg B; Roberts PJ; Heinrich MC; Tuveson DA; Singer S; Janicek M; Fletcher JA; Silverman SG; Silberman SL; Capdeville R; Kiese B; Peng B; Dimitrijevic S; Druker BJ; Corless C; Fletcher CD; Joensuu H
N Engl J Med; 2002 Aug; 347(7):472-80. PubMed ID: 12181401
[TBL] [Abstract][Full Text] [Related]
12. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
[TBL] [Abstract][Full Text] [Related]
13. Apoptotic and anti-angiogenic strategies in liver and gastrointestinal malignancies.
Kountouras J; Zavos C; Chatzopoulos D
J Surg Oncol; 2005 Jun; 90(4):249-59. PubMed ID: 15906369
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis.
Määttä M; Soini Y; Liakka A; Autio-Harmainen H
Clin Cancer Res; 2000 Jul; 6(7):2726-34. PubMed ID: 10914717
[TBL] [Abstract][Full Text] [Related]
15. [Hepatocellular carcinoma: molecular pathogenesis and novel targets for therapy].
Marquardt JU; Galle PR; Teufel A
Dtsch Med Wochenschr; 2012 Apr; 137(16):855-60. PubMed ID: 22495921
[TBL] [Abstract][Full Text] [Related]
16. Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors.
de Jong FA; Verweij J
Expert Rev Anticancer Ther; 2003 Dec; 3(6):757-66. PubMed ID: 14686698
[TBL] [Abstract][Full Text] [Related]
17. Targeting dynamics of subclones of GI, liver and pancreatic cancers.
Ziogas DE; Glantzounis G; Liakakos T; Roukos DH
Expert Rev Gastroenterol Hepatol; 2016 Jul; 10(7):773-6. PubMed ID: 27143511
[No Abstract] [Full Text] [Related]
18. [At last, an effective therapy for non-differentiated GI sarcomas (gastro intestinal stromal tumor)].
Des Guetz G; De Mestier P; Pierga JY
J Chir (Paris); 2002 Oct; 139(5):268-73. PubMed ID: 12410126
[TBL] [Abstract][Full Text] [Related]
19. Targeted agents for sarcoma: is individualized therapy possible in such a diverse tumor type?
Riedel RF
Semin Oncol; 2011 Oct; 38 Suppl 3():S30-42. PubMed ID: 22055970
[TBL] [Abstract][Full Text] [Related]
20. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT.
Bauer S; Corless CL; Heinrich MC; Dirsch O; Antoch G; Kanja J; Seeber S; Schütte J
Cancer Chemother Pharmacol; 2003 Mar; 51(3):261-5. PubMed ID: 12655446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
